Myriad Genetics Inc, a leader in molecular diagnostic testing and precision medicine, announced that the US Food and Drug Administration (FDA) has approved the MyChoice CDx test as the companion ...
Breast cancer has witnessed the emergence of innovative screening technologies designed specifically for accessibility and comfort. Scientifically validated, portable solutions are now enabling early ...
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice: Ingelheim, Germany Thursday, March 19, 2026, 14:00 Hrs [IST] World Parasite A ...
Melius MicroBiomics receives Australian Dealings Involving Intentional Release licence as key step toward clinical evaluation: Vancouver, BC Thursday, March 19, 2026, 18:00 Hrs [I ...
Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia: Sunnyvale, California Thu ...
Patients to get new medicines up to six months sooner under new joint MHRA-NICE approval process: United Kingdom Thursday, March 19, 2026, 13:00 Hrs [IST] The MHRA and NICE aligne ...
Lupin Manufacturing Solutions expands Dabhasa manufacturing facility: Our Bureau, Mumbai Thursday, March 19, 2026, 13:30 Hrs [IST] Lupin Manufacturing Solutions (LMS), a global CR ...
Axplora plans $60 million investment programme at its Farmabios site in Gropello Cairoli: Germany Thursday, March 19, 2026, 16:00 Hrs [IST] Axplora, a global leader in complex act ...
Zydus Lifesciences launches Aerolife Mini, to simplify inhaler use for asthma and COPD patients: Our Bureau, Mumbai Thursday, March 19, 2026, 13:15 Hrs [IST] Zydus Lifesciences Li ...
US FDA grants Breakthrough Therapy designation to Sanofi’s venglustat for type 3 Gaucher disease: Paris Sanofi announced that the US Fo ...
Samsung Bioepis inks partnership agreement with Sandoz for up to five next-generation biosimilar candidates: Incheon, Korea Thursday, March 19, 2026, 11:00 Hrs [IST] Samsung Bioep ...
Sobi presents positive results from EMBRACE phase 2a study of emapalumab in interferon-gamma-driven sepsis at ISICEM: Stockholm Thursday, March 19, 2026, 12:00 Hrs [IST] Sobi, a g ...